Applied Filters
University of California to be granted CRISPR patent
The University of California will soon be granted a patent related to the gene-editing technology CRISPR, according to a notice of allowance by the US Patent and Trademark Office.
Victory for Mayo in neurological disorder patent dispute
In a victory for Mayo Collaborative Services, a US Court has ruled that four claims in a patent, of which Athena Diagnostics is the exclusive licensee, are invalid.
GSK and Merck KGaA unite in €3.7bn immunotherapy deal
UK headquartered GSK has made another move in the oncology space, signing a potential €3.7 billion immunotherapy deal with Germany-based Merck KGaA.
Merck signs DNA licensing deal with Vertex
German pharmaceutical company Merck Group has granted US biotech firm Vertex a licence to two DNA-dependent protein kinases inhibitors.
Sequenom and Illumina prevail in UK confidentiality dispute
The England and Wales High Court has ruled in favour of Sequenom and Illumina, after the companies asked the court to rule that they were entitled to receive confidential information in legal proceedings against three competitors without additional restriction.
Australian court allows application for cattle genome patent
The Federal Court of Australia has allowed an application for a cattle genome patent, following a legal battle.
EPO invalidates Pacific Biosciences patent in Oxford Nanopore dispute
The European Patent Office has revoked a patent held by a US biotechnology company, Pacific Biosciences, after its UK-based rival Oxford Nanopore Technologies challenged the validity of the patent.
Locus licenses CRISPR tech to Janssen in potential $818m deal
US-based Locus Biosciences has announced it will license its CRISPR-Cas3 technology to Janssen, a subsidiary of American pharmaceutical company Johnson & Johnson, in a deal worth a potential $818 million.
Court invalidates Illumina patents in Ariosa row
Ariosa Diagnostics, a subsidiary of Swiss healthcare firm Roche, has won a patent dispute with American biotechnology firm Illumina.
ERS Genomics signs CRISPR deal with Lonza
ERS Genomics has signed a deal with Swiss company Lonza Pharma & Biotech to provide access to CRISPR/Cas9 technology.
